REVASCULARIZATION
REDEFINED
Precision Crossing and Vessel Preparation Made Safe
Santreva-ATK is an all-in-one, large profile, manually-controlled, and guidewire-free CTO crossing solution, with full force range and control to tackle the wide range of plaque morphologies in femoropopliteal lesions, without damaging the vessel wall.
Wire-Free Intraplaque Crossing and One-Step Vessel Preparation
One device. One pass.
0.008” thick cutting loop initiates channel formation by puncturing and dissecting plaque, even in severely calcified lesions
Torpedo shaped tip atraumatically traverses and compresses plaque laterally against the vessel wall
The large nitinol profile centering system provides self-guided intraluminal positional control and further dissects and compresses the plaque locally in the lateral direction, without harming the vessel wall. The channel created in the antegrade direction is large enough for imaging catheters to be immediately used and completes vessel preparation for further treatment.
The catheter shaft acts as a delivery system, connecting the palm sized ergonomic handle and the catheter tip, providing the force and control necessary to traverse plaque in a single pass
With Santreva-ATK, no external power source is needed. The torque wheel enables the operator to manually control advancement of the device, while providing tactile feedback regarding lesion morphology
Palm sized ergonomic handle offers comfort and control
Safe, rapid, intraplaque placement of wire after crossing
Santreva-ATK Specifications
|
Guide Catheters With 6Fr or > guide catheter |
6Fr or larger Minimum 1.78mm ID |
|
Guide Sheaths or Introducer Without a guide catheter |
5Fr or larger Minimum 1.78mm ID |
|
Guidewire |
0.014″ |
|
Description Santreva™-ATK Endovascular Revascularization Catheter |
Catalog Number AAS-1963-02 |
Tackle any complex lesion
including CTOs, irrespective of calcification or lesion length.
Santreva-ATK combines three mechanisms to revascularize – wire-free crossing, intraplaque compression and channel formation – in a single step with minimal risk of embolism, flow-limiting dissection, or major perforation.1
See how Santreva-ATK performed in the RESTOR-1 pivotal trial.
1RESTOR-1 Pivotal Clinical Study, data on file and Instructions for Use (IFU)